Cambridge Healthtech Institute’s 11th Annual
Cell Therapy CMC & Manufacturing
Reducing Costs and Complexity in Cell Therapy Scale Up
August 12-13, 2026
Cambridge Healthtech Institute’s 11th Annual Cell Therapy CMC and Manufacturing program brings together leaders advancing automation, manufacturing, point-of-care models, in vivo CAR T platforms, and next-generation manufacturing strategies for both late-stage and emerging cell therapies. Sessions highlight the need to reduce costs in manufacturing, improve process development, and the role of and real-world experience with decentralized manufacturing. Additional focus areas include CMC and regulatory considerations for in vivo CAR T, manufacturing for autoimmune indications, digital and AI-driven facility modernization, late-stage drug product and delivery challenges, and platform-specific strategies for iPSCs, NKs, gamma deltas, TILs, and tissue-engineered products. Case studies throughout provide practical lessons for scalable, efficient, and patient-aligned manufacturing.
Coverage will include, but is not limited to:
Advances in Cell Therapy Manufacturing
- Reducing costs in cell therapy manufacturing—case studies from Kite Gilead, JnJ, BMS
- Latest developments in allogeneic cell therapy manufacturing
- Engineering strategies for off-the-shelf allogenic cell therapies
- Supply chain management and the role of cross industry technology
Point-of-Care Manufacturing and Decentralized Approaches
- Case studies of POC manufacturing
- Industry experience of POC manufacturing—challenges, costs, regulatory feedback
- Role of hospitals and clinicians in POC manufacturing—importance of training
- Cryopreservation and shipping
- Centralized vs. decentralized approaches to cell therapy development
In vivo CAR T Therapy
- CMC Challenges for in vivo CAR T—updates from Interius, Umoja, Capstan
- Using lentiviral platforms for in vivo CAR T
- Regulatory consideration for establishing safety and effectiveness
- Release testing requirements
- What is the product?
Cell Therapies for Autoimmune Disease
- Manufacturing cell therapies for autoimmune
- How are companies preparing for demand
- Differences vs. oncology indications
- Process development challenges
Data, AI, Digitalization in Cell Therapy Manufacturing
- Implementing AI and digitalization in cell therapy manufacturing
- Next-generation facilities and technologies for automation
- The role of automation and robotics in improving cell therapy manufacturing
Manufacturing Strategies for Emerging Cell Therapies
The deadline for priority consideration is January 23, 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: